Because invadosome formation in lung fibroblasts is strongly associated with the severity of pulmonary fibrosis, targeting the hypoxic induction of invadosomes with combined LPA1 and RTK inhibitors may benefit patients with IPF. The gene discussed is LPAR1; the disease is pulmonary fibrosis.